CDDF board members are distinguished and experienced pre-clinical and clinical investigators who are devoted to the development of cancer drugs. They have experience in advising on or reviewing drug development strategies in pre-clinical and early clinical development, designing phase I/IIl clinical trials using novel designs and endpoints to speed up and optimise the overall drug development programmes, and to avoid suboptimal drug development strategies.
- Prof. Ruth Plummer – Chairperson
- Prof. Eva Skovlund – Vice-Chairperson
- Prof. Axel Glasmacher –Treasurer
- Prof. Jaap Verweij – Managing Director
- Dr. Catarina Edfjäll
- Prof. Mark Lawler
- Prof. Stefan Symeonides